Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: An observational study of 22 cases

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Exercise training is associated with reduced pains from the musculoskeletal system in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Associations between birth weight and glucose intolerance in adulthood among Greenlandic Inuit

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Work matters: Diabetes and worklife in the second diabetes attitudes, wishes and needs (DAWN2) study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Migration, body mass index and gestational diabetes mellitus among women in Denmark 2004-2015: a register-based study

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  2. Genome-wide association study of circulating levels of glucagon during an oral glucose tolerance test

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Migration, body mass index and gestational diabetes mellitus among women in Denmark 2004-2015: a register-based study

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  4. Home blood pressure in pregnancy-the upper reference limit

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIM: To report glycemic control and pregnancy outcome in pregnant women with type 1 diabetes on insulin degludec.

METHODS: Twenty-two women with type 1 diabetes on degludec from conception to delivery between 2014 and 2018 were compared with 51 pregnant women with type 1 diabetes on glargine.

RESULTS: Baseline characteristics were comparable, however HbA1c was higher at median 9 (range 5-19) weeks in women on degludec compared to women on glargine (6.9% (5.7-8.7); (52 (39-72) mmol/mol) versus 6.4% (5.1-10.1); (46 (32-87) mmol/mol), p = 0.04). HbA1c was similar in late pregnancy (6.3% (5.6-7.1); (45 (38-54) mmol/mol) versus 6.1% (5.2-9.0); (43 (33-75) mmol/mol), p = 0.28). The prevalence of severe hypoglycemia was 3 (14%) versus 6 (12%), p = 1.00 during pregnancy and 0 versus 1, p = 1.00 during hospital admittance after delivery. Most women on degludec used one daily injection in early (20 (91%) versus 25 (49%), p = 0.001) and late pregnancy (21 (96%) versus 19 (37%), p < 0.001). No significant differences in obstetrical and neonatal outcomes were found between the groups. Maternal hospital admittance after delivery was 2 (1-5) versus 3 (2-11) days (p = 0.004).

CONCLUSIONS: Glycemic control in late pregnancy, severe hypoglycemia during and immediately after pregnancy as well as pregnancy outcome were comparable in women on degludec or glargine. Degludec initiated preconceptionally may be continued in pregnancy.

Original languageEnglish
JournalDiabetes Research and Clinical Practice
Volume152
Pages (from-to)58-64
Number of pages7
ISSN0168-8227
DOIs
Publication statusPublished - 1 Jun 2019

    Research areas

  • Degludec, Glycemic control, Hypoglycemia, Pregnancy outcome, Type 1 diabetes

ID: 57290897